Studies into the pathophysiology of schizophrenia have consistently demonstrated a dysfunction of dopamine (DA) system regulation in this disorder. This includes hyper-responsivity to DA agonists, the therapeutic efficacy of DA antagonists, and augmented striatal DA release in response to amphetamine. Nonetheless, there is little evidence for a pathological alteration with the DA system itself in schizophrenia. Instead, it is suggested that the disturbance lies in the manner by which the DA system is regulated. Recently, rodent models of schizophrenia have been advanced based on developmental disruption that recapitulates many of the symptoms observed in human schizophrenia patients. We found that administration of the mitotoxin methylazoxymethanol acetate (MAM) to rats at gestational day 17 leads to adult rats that exhibit neuroanatomical, pharmacological, and behavioral characteristics consistent with schizophrenia. These rats also exhibit hyperactivity within the ventral subiculum of the hippocampus that corresponds to a loss of parvalbumin-containing interneurons. This hyperactivity causes an increase in the population activity of the DA neurons (i.e., more DA neurons are firing spontaneously), thus increasing the responsivity of the DA system to stimuli. When the ventral subiculum is inactivated, DA neuron population activity is restored to baseline, and the hyperresponsivity to amphetamine is normalized to that observed in control rats. These findings demonstrate a direct link between the hippocampal pathophysiology, interneuronal alterations, and hyperdopaminergic state observed in the schizophrenia patient. Moreover, this suggests an alternate pharmacotherapeutic approach based on the normalization of hippocampal activity in the treatment of schizophrenia in humans.
INTRODUCTION
Schizophrenia is a psychotic disorder characterized by a wide variety of symptoms, which can be divided into three groups; cognitive, positive and negative symptoms (Andreasen, 1995) . The cognitive symptoms are largely deficits related to memory and executive function. The positive symptoms include psychosis and are characterized by delusions and hallucinations, while the negative symptoms largely relate to blunted affect, avolition and anhedonia (Andreasen, 1995) . Given the wide range of neuropsychiatric symptoms, it is perhaps not surprising that the neuropathology of schizophrenia is both subtle and widespread, involving both cortical and subcortical deficits. Although there are a number of pathologies consistently observed in the schizophrenia patient, as yet, there is no clear primary origin of the disease.
THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA
The dopamine hypothesis suggests that the overactivity of mesolimbic dopamine transmission underlies the positive symptoms of the disease (Laurelle and Abi-Dargham, 1999; Carlsson et al., 2000; Abi-Dargham, 2004 ). This hypothesis is based upon a number of observations, the most prominent being that all current antipsychotic drugs bind to and block the dopamine D 2 receptor (Miyamoto et al., 2004) . Further evidence for dopamine hyperfunction stems from the ability of dopamine agonists to exacerbate psychosis, and imaging studies demonstrating increased amphetamine-induced dopamine release in schizophrenia patients that correlates with exacerbation of psychosis (Laruelle and Abi-Dargham, 1999; AbiDartgham, 2004) .
Although there is significant well-established data in support of the dopamine hypothesis, a major caveat of this theory is that there appears to be no primary pathology in the midbrain dopamine system of schizophrenia patients. This has led researchers to propose that, although the dopamine system appears normal in the schizophrenia patient, the primary disease pathology lies upstream of the ventral mesencephalon. Moreover, it is pathology in these regions that results in the aberrant regulation of ascending dopamine transmission (Grace, 1991; 2000; Laruelle and Abi-Dargham, 1999; Carlsson et al., 2000; Abi-Dargham, 2004) . At present the regions associated with this dysregulation are unknown; however, there is a significant literature demonstrating that, in addition to dopamine hyperactivity, schizophrenia is associated with alterations in afferent structures to the VTA with two primary regions being the medial prefrontal cortex (thought to be largely associated with cognitive deficits) (Lewis and Gonzalez-Burgos, 2008 ) and the hippocampus, a temporal lobe structure associated with learning and memory (Moses et al., 2002; Squire et al., 2004) .
Hippocampal Dysfunction in Schizophrenia
Evidence for abnormal hippocampal structure and function in schizophrenia has come largely from postmortem and neuro-imaging studies. More specifically, a postmortem reduction in hippocampal volume is one of the more consistent structural abnormalities observed in schizophrenia patients (Nelson et al., 1998; Harrison, 1999; Shenton et al., 2001; Heckers and Konradi, 2002; Heckers, 2004) . How this affects hippocampal information processing is not entirely known; however, recent functional imaging studies have suggested augmented hippocampal activity at rest and an abnormal information processing during the performance of memory retrieval tasks (Nordahl et al., 1996; Heckers et al., 1998; Medoff et al., 2001; Meyer-Lindenberg et al., 2001; Lahti et al., 2006; Weiss et al., 2006) . Thus, hippocampal dysfunction has been demonstrated to contribute not only to impaired information processing but also to the positive symptoms of the disease. Furthermore, the role for the hippocampus in psychosis suggests an interaction with the midbrain dopamine system. Indeed the ventral subiculum of the hippocampus is a region that potently modulates dopamine neuron activity (Legault and Wise, 1999; Floresco et al., 2003; Lodge and Grace, 2006) . Thus, rodent studies have demonstrated that NMDA activation of the ventral subiculum significantly increases dopamine neuron population activity (the number of dopamine neurons firing spontaneously) which is correlated with increased extrasynaptic DA efflux in the nucleus accumbens. Since the hippocampus doesn't directly innervate the VTA, it has been suggested that the subiculum modulation of DA neuron activity is dependent on a polysynaptic (vHipp-NAc-VP) projection (Floresco et al., 2003; Lodge and Grace, 2006) . Given evidence correlating hippocampal dysfunction with psychosis in schizophrenia (Harrison, 2004) , we propose that aberrant hippocampal activity may underlie the DA dysregulation in this disorder.
The pathogenesis of the hippocampal abnormalities in schizophrenia is still largely unknown. Furthermore, although polymorphisms in a number of hippocampal genes have been identified as potential risk factors, there is no selective genetic dysfunction associated with the disease (MeyerLindenberg and Weinberger, 2006) . Thus, increasing evidence has suggested that developmental alterations, specifically during cortical development, lead to prefrontal and hippocampal dysfunctions (Waddington et al., 1999; Marenco and Weinberger, 2000; Lewis and Levitt, 2002; Moore et al., 2006) . The cause of the developmental alterations is not known; however, suggestions have included prenatal viral infections (Murray et al., 1992; Hornig and Lipkin, 2001; Pearce, 2001 ), trauma and birth complications (McNeil, 1995; McNeil et al., 2000) . Nonetheless it seems likely that schizophrenia is, as least in part, a developmental disorder resulting in aberrant cortical (prefrontal and hippocampal) regulation and associated with increased dopaminergic activity.
The MAM-Treated Rat as a Developmental Model of Schizophrenia
Recent studies have made use of these observations to produce a developmental disruption animal model of schizophrenia to further enable research into the pathophysiology of this disorder (Grace and Moore, 1998; Flagstad et al., 2004; Moore et al., 2006) . One model that has substantial face validity utilizes the administration of the DNA methylating agent, methylazoxymethanol acetate (MAM) to pregnant dams on gestational day (GD) 17 (Grace and Moore, 1998; Flagstad et al., 2004; Goto and Grace, 2006; Moore et al., 2006; ). This rodent model intentionally utilizes a non-selective developmental disruption and as such has a high degree of construct validity, in that there is no selective genetic manipulation or loss of a specific brain structure; consistent with that observed in the human schizophrenia patient. Furthermore, the deficits observed in this model parallel those observed in schizophrenia patients including: anatomical changes (thinning of limbic cortices with increased packing density (Moore et al., 2006) ), behavioral deficits (decreased prepulse inhibition of startle, disruption in learning new response contingencies, increased responses to PCP and amphetamine (Flagstad et al., 2004; Moore et al., 2006) , an increased sensitivity to stress (Goto and Grace, 2006) , executive behavioral impairment (Gourevitch et al., 2004) , perseverative errors and deficits in latent inhibition (Flagstad et al., 2004) , and social impairment (Talamini et al., 1998; 2000) , and disruption of rhythmic activity in frontal cortex (Goto and Grace, 2006) . As such, the MAM GD17 model has been reported to produce anatomical and behavioral disruptions that exhibit a high degree of face and construct validity with that observed in schizophrenia in humans.
Aberrant Dopamine Signaling in the MAM Model
Using this highly validated experimental model, we recently attempted to determine those factors responsible for the aberrant dopamine system responsivity consistently observed in rodent models of psychosis as well as in schizophrenia in humans . Specifically, the activity of the midbrain dopamine system was examined by single unit in vivo extracellular recordings from identified dopamine neurons of the rat VTA . Such an approach in untreated rats has provided a model of sub-cortical dopamine function that posits the mesolimbic dopamine system is regulated via two independent mechanisms: 1) transient or "phasic" dopamine release driven by dopamine neuron burst firing, and 2) extrasynaptic or "tonic" levels of dopamine dependent on basal dopamine neuron activity and regulated via presynaptic inputs . Dopamine neuron burst firing induces a large transient increase in perisynaptic dopamine (Chergui et al., 1994) and is considered to be the functionally relevant signal that encodes reward prediction or incentive-salience (Berridge and Robinson, 1998; Schultz, 1998) , whereas tonic dopamine transmission occurs on a much slower scale and is proposed to set the background level of dopamine system activation (Grace, 1991) . Using this approach we have recently determined that rats treated prenatally with MAM and examined as adults, display a pathologically enhanced dopamine neuron drive . More specifically, this hyperactivity is observed as an increase in the number of spontaneously active dopamine neurons (FIG. 1A) , an index of tonic dopamine transmission that is highly correlated with changes in extrasynaptic dopamine levels in forebrain structures (Floresco et al., 2003) . Such an increase in dopamine transmission not only produces an augmented dopamine release in terminal regions, but may also result in a considerably amplified phasic response when the animal is presented with otherwise non-salient events or objects (Kapur, 2003; Lodge and Grace, 2006) .
Aberrant Hippocampal Regulation of Dopamine Signaling in the MAM Model
Given that the alteration in dopamine activity purportedly occurs secondary to cortical disruption in human schizophrenia patients, we sought to determine the cause of increased dopamine neuron activity in the MAM treated rats. Furthermore, given significant evidence of hippocampal disruption in schizophrenia and the role of the ventral subiculum in the regulation of dopamine neuron activity states, we suggest that aberrant hippocampal activity may underlie the augmented dopamine neuron function in the MAM model. This purported involvement of the ventral hippocampus in the aberrant dopamine neuron activity in the MAM model of schizophrenia has been recently examined . Specifically, inactivation of the ventral hippocampus by infusion of the sodium channel blocker, tetrodotoxin (TTX) normalized the pathologically enhanced dopamine neuron population activity observed in MAM treated rats (FIG. 1B) . Moreover, this manipulation had no significant effect on any other parameter of dopamine neuron activity in MAM rats nor did it have any observable effects on DA neuron activity in control animals . As such, it stands to reason that pathology within the hippocampus may result in an increased hippocampal output. Indeed, we have recently demonstrated an enhanced ventral hippocampal activity in MAMtreated rats using in vivo extracellular recordings . More specifically, the spontaneous activity of ventral hippocampal neurons is increased in MAM rats, expressed as a significantly greater baseline firing rate with no significant change in patterned activity at the single cell level . Thus, we propose that the augmented dopamine transmission observed in MAM animals is attributable to a pathologically enhanced hippocampal transmission and further suggest this is consistent with observations in human schizophrenia patients.
A Role for Hippocampal Hyperactivity in Human Schizophrenia
The model advanced here is consistent with hippocampal dysfunction observed in schizophrenia patients (Saykin et al., 1991; Harrison, 1999; Shenton et al., 2001) . Furthermore, recent functional imaging studies have suggested an abnormally high level of activity both during resting states (Nordahl et al., 1996; Heckers et al., 1998; Lahti et al., 2006; ) and during task performance (Medoff et al., 2001; Meyer-Lindenberg et al., 2001; Weiss et al., 2006) . In addition, hyperactivity in hippocampal regions has been proposed to FIGURE 1 Aberrant hippocampal activity is responsible for the DA hyper-responsivity in the MAM rodent model of schizophrenia. Prenatal (GD17) MAM administration results in an increased number of spontaneously active VTA dopamine neurons (A) compared to prenatal saline treated rats. This appears to be attributed to vHipp hyperactivity since inactivation of the vHipp by tetrodotoxin (light bars) normalizes the aberrant increase in DA neuron population activity in MAM rats (B), while having no observable effect in control rats (dark bars).
underlie the positive symptoms of the disorder, including abnormal thought processes, hallucinations, and delusions (Krieckhaus et al., 1992; Venables, 1992) . Finally, it is well-known that temporal lobe epilepsy, a type of hyperactivity of the hippocampus, has been associated with schizophrenia-like positive symptoms in humans (Ounsted and Lindsay, 1981) . Taken together, these data are consistent with the model suggested here in which hyperactivity within the hippocampus drives the dopamine hyperfunction (FIG. 2) .
Abnormal GABA Regulation of Hippocampal Activity in Schizophrenia
The mechanisms underlying the pathological enhancement of hippocampal output are not currently known; however, we propose that the augmented hippocampal output may be attributed to a reduction in inhibitory GABAergic transmission within the hippocampus. Evidence for GABA dysfunction in schizophrenia is abundant (Benes and Berretta, 2001; Benes, 2002; Reynolds et al., 2002; Lewis et al., 2005; Benes et al., 2007) . Thus, a number of postmortem studies of cortical GABA signaling in schizophrenia patients have provided consistent evidence for diminished GABA activity. More specifically, a diminished expression of glutamic acid decarboxylase (GAD)-1 mRNA and associated decrease in GAD-67 protein are observed postmortem throughout the cortex of human schizophrenia patients (Akbarian et al., 1995; Volk et al., 2000; Hashimoto et al., 2003) . GAD is an enzyme critical for GABA biosynthesis and as such a deficit in GAD expression in the hippocampus may result in an aberrant inhibition of hippocampal transmission. More recently, there has been increasing evidence that the GAD deficits in schizophrenia may be largely restricted to a specific class of GABAergic interneurons, specifically those containing the calcium binding protein parvalbumin (Lewis et al., 2005) . Consistent with this, we have recent evidence for a selective decrease in parvalbumin positive neurons throughout the ventral subiculum of the hippocampus (but not in the dorsal subiculum) in the MAM model . Furthermore, a decrease in hippocampal FIGURE 2 Schematic depicting the aberrant regulation of the dopamine system in schizophrenia. Hippocampal hyperactivity (suggested to be associated with a decrease in GABA transmission) results in an increased activation of the nucleus accumbens (NAc). The subsequent increase in NAc output inhibits the ventral pallidum (VP) resulting in the disinhibition of VTA dopamine neurons.
parvalbumin-containing interneurons is a consistent observation in a diverse variety of animal models of schizophrenia, including the MAM model (Penschuck et al., 2006) , the chronic phencyclidine (PCP) model (Abdul-Monim et al., 2007) , and in rats reared in rearing isolation (Harte et al., 2007) . As such, we propose that the augmented hippocampal output is a consequence of a diminished GABAergic regulation of pyramidal cell output.
CONCLUSION
The model advanced here is largely based on recent data obtained using a verified animal model of schizophrenia and correlated with observations of schizophrenia in humans. Thus, we have recently demonstrated that the pathological increase in tonic DA transmission observed in MAM rats is likely attributable to hyperactivity within the ventral hippocampus. Moreover, we propose that the hippocampal dysfunction consistently observed in schizophrenia patients is the basis for the dopamine dysregulation in this disorder. We posit that the hippocampal hyperactivity may be a consequence of a deficit in intrinsic GABA signaling. Such an understanding of the functional interactions among these systems and how disruption within these circuits affects information processing is central to gaining a better understanding of the disease pathophysiology and suggests an alternate pharmacotherapeutic approach based on the normalization of hippocampal activity in the treatment of schizophrenia.
